Member Info for Fruitsnveg

My horizon doesn't go beyond P2's, and 2024 at the very latest. If P2's yield tantalising data, I can see the drug joining an established respiro BP pipeline and $$$cash in the bank for Synairgen to either move on to the next unmet need or niche clinical area involving inhaled technology, or, to co-develop SNG001 with a BP. Funding will definitley not be a talking point after that IMO. As I see it there will be a fork in the road after P2's start - big deal for top data, or no deal and uncertainty for poor data or failure. My eggs remain in Basket A. And I wouldn't count on any BP waiting around until read-outs and P2 data publishing. Anyone with skin in this game will already have done some DD on SNG001 and be ready to fend off competition early if the data speaks to their pipeline. Still unknowns, but i'm not counting on long-range here. Not yet.

Thanks Jint

Jint

" they intimated that they would be using the Casanova assay tests in reply to a question were they using Thermo Fisher for tests, to which they replied no." It could be someone other than Casanova, unless they expressly said it would be Casanova?

Agree. Messrs Coulda, Woulda and Shoulda, tirelessly looking for every crack in the armour, every break in the fence, chipping away with every negative comment on all things SNG since 2020. It's like watching historical fantasy fiction for 3 years with no ad breaks.

It counts as one of your 5 a day.

There you go, talking to yourselves again DocD.

Everyone's an expert, etc.

Sorry aether, that was no reflection on you.

"Can anyone give any examples of knowing anyone more boring than aether?"

Knowing you?

:-)

You go on believing your own alternative reality there Doc.Dan. Genuine investors will recognise the value proposition of already having valuable positive Mers lab data for SNG001. One less box to tick, one more treatment to potentially target should the need ever arise.

"No danger to the world" says epidemiologist Dr. Daneeka.

Meanwhile, the WHO on 29 August 2023 reported that:

"Human-to-human transmission of MERS-CoV in healthcare settings has been associated with delays in recognizing the early symptoms of MERS-CoV infection, slow triage of suspected cases, and delays in implementing infection, prevention, and control (IPC) measures.

The crude case fatality rate for Mers is 36%."

The threat is not about proximity to camel populations or today, it's about a day in the future when some hospital ward starts to fill with patients in pulmonary distress, as happened without warning in China and Lombardy in the first days of Covid. Remember how UK gov were stating the little known virus caught from bats, was "very low risk"? Hindsight is a wonderful thing. Any data Synairgen has on SNG001's efficacy against Mers should be seen as a positive, something that could prove useful in a future pandemic. As Alpha-dog wisely notes "The nightmare scenario though is MERS and Covid co-infection in an immunocompromised individual with potential for a chimera, a hybrid with MERS pathogenicity and Covid 19 transmissibility".

SBM,

I'd like to know which "biotechs on the nasdaq" give you a such a "large return" on your investment that negates the massive hit you'd have taken selling at 7p here...? I know of none.

Regarding Mers, it's worth noting that

"IFN-β has been shown in the lab to protect cells from infection from a broad range of respiratory viruses that cause lower respiratory illness including highly pathogenic coronavirus strains, INCLUDING MERS-CoV, SARS-CoV and SARS-CoV-2"

Source: Synairgen website

Funny you should ask. Toscafund Asset Management LLP own about 1.28 million shares....which is probably 1.275 more shares than you, Costas. Interestingly, they are a major investor in Circle Health Ltd. And they were also one of Spire Healthcare's largest investors. No dodo's one would assume, probably did their homework.

Small, quick studies to add to the existing data sets. Nothing more sophisticated needed. BP like what they see, they take it on. They don’t, we got a problem. Simple as. I expect P2s and that catalyst to happen much sooner that end 2024.

It was only a matter of time after Sakura of Wikedpidia-copy-and- paste-fame, was outed as a lying non-Scientist trader, that the reverent Doc.Daneeka would show up to defend them. Nothing new, same as it ever was for anyone who follows this tired routine.

Sakura: you never explained how you nebulised patients with IFN at CCU when IFN was only used intranasally at that time at CCU. Or did you "boss" David Tyrell not explain it to you?? Waiting for your answer....with "bated (baited) breath" breath.....

Doc.Daneeka: It's 'baiting' not 'bating'.

Sakura: It's 'bait' not 'bate'.

Anyone would think you were the same poster! Hang on a secon....

Yawn.

Sakura never did explain how they "used the same method of administering the drug using a nebuliser so that it gets into the lungs" , when it's a fact that alpha and beta IFNs were administered only intranasally at the unit which Sakura claims to have worked in (the CCU in Hampshire). Bit of a slip up there? Sakura took flight the last time they were challenged on this. Perhaps their latest apparition here will afford us more detail behind their claims?

One thing I do believe is their explanation of why they are actually here, which they rather stupidly provided to another BB. To quote " A few weeks ago some Charlie on here told us we should be investing in SNG valued at several 100 million. I took the bate (sic) to find it was a technology I knew little about".

Oh dear.

I can understand why Professional and Mani would not want a competent CFO on board.